<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Adjunctive therapy for patients with resected early stage colorectal cancer: Diet, exercise, NSAIDs, and vitamin D
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Adjunctive therapy for patients with resected early stage colorectal cancer: Diet, exercise, NSAIDs, and vitamin D
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Adjunctive therapy for patients with resected early stage colorectal cancer: Diet, exercise, NSAIDs, and vitamin D
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey W Clark, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Hanna K Sanoff, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard M Goldberg, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sonali M Shah, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 31, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H3766171594">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surgical resection is the only curative treatment for locoregional colon cancer. Outcome is most closely related to the extent of disease at presentation. (See
         <a class="medical medical_review" href="/z/d/html/2507.html" rel="external">
          "Overview of the management of primary colon cancer", section on 'Prognosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/106743.html" rel="external">
          "Overview of the management of rectal adenocarcinoma", section on 'Prognosis'
         </a>
         .)
        </p>
        <p>
         Among patients who have undergone potentially curative resection for colorectal cancer (CRC), disease recurrence is thought to arise from clinically occult micrometastases that are present at the time of surgery. The goal of postoperative (adjuvant) therapy is to eradicate these micrometastases, thereby increasing the cure rate. In colon cancer, the benefits of adjuvant chemotherapy have been most clearly demonstrated in stage III (node-positive  (
         <a class="graphic graphic_table graphicRef111438" href="/z/d/graphic/111438.html" rel="external">
          table 1
         </a>
         )) colon cancer, whereas benefit in stage II disease remains controversial. (See
         <a class="medical medical_review" href="/z/d/html/2471.html" rel="external">
          "Adjuvant therapy for resected stage III (node-positive) colon cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15256.html" rel="external">
          "Adjuvant therapy for resected stage II colon cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2529.html" rel="external">
          "Adjuvant therapy for resected rectal adenocarcinoma in patients not receiving neoadjuvant therapy"
         </a>
         .)
        </p>
        <p>
         Patients with rectal cancer have a higher risk of local recurrence as compared with colon cancer, and the adjuvant strategy often includes radiation therapy as well as chemotherapy for both stage II and III disease  (
         <a class="graphic graphic_table graphicRef111438" href="/z/d/graphic/111438.html" rel="external">
          table 1
         </a>
         ). Neoadjuvant or induction chemoradiotherapy is an increasingly used option for patients with locally advanced rectal adenocarcinomas, with additional chemotherapy to eradicate micrometastases administered postoperatively; however, in some cases, chemotherapy can also be given preoperatively. (See
         <a class="medical medical_review" href="/z/d/html/2529.html" rel="external">
          "Adjuvant therapy for resected rectal adenocarcinoma in patients not receiving neoadjuvant therapy", section on 'Stage II to III disease following transabdominal surgery'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/118234.html" rel="external">
          "Adjuvant therapy after neoadjuvant therapy for rectal cancer", section on 'Benefit of postoperative chemotherapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2468.html" rel="external">
          "Neoadjuvant therapy for rectal adenocarcinoma", section on 'Total neoadjuvant therapy for locally advanced tumors'
         </a>
         .)
        </p>
        <p>
         Beyond the benefits of chemotherapy and radiation therapy, several adjunctive factors have been associated with improved outcomes after treatment of early stage CRC, including interventions to achieve energy balance (ie, maintaining a healthy body weight, higher levels of physical activity), intake of
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and other nonsteroidal anti-inflammatory drugs (NSAIDs), vitamin D status, and coffee consumption. The data linking these adjunctive treatments to outcomes will be addressed here. A more in-depth discussion on the roles of diet, physical activity, and body weight in cancer survivors is provided elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/14222.html" rel="external">
          "The roles of diet, physical activity, and body weight in cancer survivors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1273516514">
         <span class="h1">
          DIET AND EXERCISE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the mounting evidence that diet and exercise can modify prognosis, patients with early stage CRC should be encouraged to maintain a healthy weight and exercise regularly. The role of a healthy diet, as well as the effect of specific dietary components including nuts, coffee, and fiber, is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/14222.html" rel="external">
          "The roles of diet, physical activity, and body weight in cancer survivors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H754480570">
         <span class="h1">
          ASPIRIN AND OTHER NSAIDS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several observational studies suggest that use of
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and other nonsteroidal anti-inflammatory drugs (NSAIDs) may improve survival among patients receiving treatment for early CRC, although it is not clear that all patients benefit. Many oncologists, including some of the authors and editors associated with this topic review, recommend a daily dose of aspirin to patients with resected early stage CRC unless they have a contraindication (preexisting coagulopathy, on anticoagulants, history of gastritis or peptic ulcer disease). The optimal dose is not established, although the most common range is 75 to 325 mg daily. It is premature to consider testing individual patients for mutations in the
         <em>
          PIK3CA
         </em>
         gene in order to make decisions about postcancer aspirin use.
        </p>
        <p>
         Numerous observational studies and randomized trials [
         <a href="#rid1">
          1-3
         </a>
         ] have demonstrated the efficacy of
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         against the development of colorectal adenomas and CRC through its actions as an inhibitor of the cyclooxygenase 2 (COX-2) pathway. This pathway is overexpressed in 80 to 85 percent of CRCs. (See
         <a class="medical medical_review" href="/z/d/html/2600.html" rel="external">
          "NSAIDs (including aspirin): Role in prevention of colorectal cancer"
         </a>
         .)
        </p>
        <p>
         Many (but not all [
         <a href="#rid4">
          4-6
         </a>
         ]) observational studies also suggest that use of
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and other NSAIDs may also improve survival among patients receiving treatment for early CRC [
         <a href="#rid7">
          7-17
         </a>
         ]. As an example, in a report of patients with CRC who were participating in the Nurses' Health Study and the Health Professionals Follow-up Study, aspirin users had a significant 29 percent lower cancer-specific mortality and a 21 percent lower overall mortality than nonusers [
         <a href="#rid7">
          7
         </a>
         ]. The reduction in mortality was even greater among patients who initiated aspirin use after cancer diagnosis than among patients who used it before, and benefit was limited to those whose tumors overexpressed COX-2. Benefits were similar in patients who received standard adjuvant chemotherapy and those who did not, and in those with stage I, II, and III disease at diagnosis. Very few of the studies addressed the potential for harm with aspirin use [
         <a href="#rid15">
          15
         </a>
         ], and none addressed the appropriate dose.
        </p>
        <p>
         These data suggest that
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         may influence the biology of established CRCs after potentially curative resection. However, all of the available data are from observational studies, and prospective confirmation of the benefit of aspirin in a randomized trial is needed before routine use of aspirin or any other NSAID can be routinely recommended, given the potential for harm (eg, gastrointestinal bleeding). One prospective randomized trial (the ASPREE trial) showed that low-dose aspirin actually increased mortality from CRC (as well as other anatomic sites), although CRC mortality was not prespecified as an endpoint, follow-up was short (median 4.7 years), and the trial was stopped prematurely, increasing the likelihood of artifactual results [
         <a href="#rid18">
          18,19
         </a>
         ].
        </p>
        <p>
         There are two other ongoing trials with CRC mortality as a prespecified endpoint (the phase III
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01150045%3Fterm%3DCALGB%2B80702%26rank%3D1&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPNSTC0mzZfUKjhgBUUmFzlU18cuNx1Xj7kIN3pfpg2bVjHvCGESQG%2Bp%2FKUWFPLadn0%3D&amp;TOPIC_ID=116457" target="_blank">
          Alliance 80702 trial
         </a>
         and the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00565708%3Fterm%3DASCOLT%26rank%3D1&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPNdtSXTyI%2BdTBeWFafn3307%2BXQa84IW3RaElrhUeAGFa6v%2BVbIAuR00kiYSnLk0tYQ%3D&amp;TOPIC_ID=116457" target="_blank">
          Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers study [ASCOLT]
         </a>
         ), and one of them, ALLIANCE, failed to find any benefit from the addition of
         <a class="drug drug_general" data-topicid="8847" href="/z/d/drug information/8847.html" rel="external">
          celecoxib
         </a>
         to oxaliplatin-based adjuvant chemotherapy in stage III colon cancer, either for disease-free or overall survival [
         <a href="#rid20">
          20
         </a>
         ]. Results from the ASCOLT trial will not be available for several years.
        </p>
        <p class="headingAnchor" id="H857555359">
         <span class="h2">
          Do all patients benefit?
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neither of these trials has selected patients according to molecular pathology, and it is not clear that all patients potentially benefit from NSAIDs:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 964 patients with CRC from the Nurses' Health Study and the Health Professionals Follow-up Study, postcancer
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         use in patients whose tumors harbor mutations in the
         <em>
          PIK3CA
         </em>
         gene (17 percent of the total) was associated with marked reduction in CRC-specific death (hazard ratio [HR] 0.18, 95% CI 0.06-0.61), whereas in patients whose cancer was wild type for
         <em>
          PIK3CA
         </em>
         , the HR for CRC death was not influenced by aspirin use (HR 0.96, 95% CI 0.69-1.32) [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A meta-analysis of five studies (including the above study) that compared postdiagnosis
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         use in CRC patients identified by
         <em>
          PIK3CA
         </em>
         status found that the overall effect of aspirin on mortality was not statistically significant (HR for overall survival 0.82, 95% CI 0.63-1.08) but that aspirin use was associated with significantly reduced overall mortality in
         <em>
          PIK3CA
         </em>
         mutation carriers (HR 0.71, 95% CI 0.51-0.99) [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A later analysis of data from the Nurses' Health Study and the Health Professionals Follow-up Study suggested that regular
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         use was associated with a lower risk of
         <em>
          BRAF
         </em>
         wild-type but not
         <em>
          BRAF
         </em>
         mutant CRC [
         <a href="#rid23">
          23
         </a>
         ]. The reduced risk of
         <em>
          BRAF
         </em>
         wild-type cancer in aspirin users was seen primarily in tumors that overexpressed prostaglandin-endoperoxide synthase 2 (PTGS2, also known as COX-2). Furthermore, the association between regular aspirin use and a lower risk of
         <em>
          BRAF
         </em>
         wild-type CRC in this study appeared to be independent of
         <em>
          PIK3CA
         </em>
         status.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         An association has also been reported between
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         benefit and
         <em>
          RAS
         </em>
         mutation status, with benefit limited to those with
         <em>
          RAS
         </em>
         wild-type tumors [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A meta-analysis of seven studies on postdiagnosis
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         therapy and seven studies on prediagnosis aspirin use concluded that postdiagnosis (but not prediagnosis) use of aspirin significantly improved overall mortality (HR 0.84, 95% CI 0.75-0.94), although the difference in CRC-specific mortality did not reach the level of statistical significance (HR 0.77, 95% CI 0.52-1.14) [
         <a href="#rid13">
          13
         </a>
         ]. The overall survival benefit appeared to be confined to those patients whose tumors overexpressed PTGS2 (HR 0.65, 95% CI 0.50-0.85) and to those with mutated
         <em>
          PIK3CA
         </em>
         (HR 0.58, 95% CI 0.37-0.90).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Others report an association between
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         benefit and tumor expression of human leukocyte antigen (HLA) class I antigens but not overexpression of PTGS2 or mutated
         <em>
          PIK3CA
         </em>
         [
         <a href="#rid10">
          10
         </a>
         ]
         <em>
          .
         </em>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Still other data suggest a differential effect of
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         according to immune checkpoint status, with lower levels of programmed cell death 1 ligand (PD-L1; resulting in lower signaling through the immune checkpoint pathway) being associated with a stronger protective effect [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/99637.html" rel="external">
          "Principles of cancer immunotherapy", section on 'Tumor evasion of immune surveillance'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         These data underscore the complexity of the interplay among
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         ,
         <em>
          PIK3CA
         </em>
         status, PTGS2 expression,
         <em>
          BRAF
         </em>
         mutations, expression of HLA class I antigens, the programmed cell death 1 protein (PD-1) immune checkpoint pathway, and potentially, other factors that have not yet been determined. Further investigations are necessary to determine the clinical significance of these findings. Given that these data are observational and derived from subset analysis, it is premature to consider testing individual patients for mutations in the
         <em>
          PIK3CA
         </em>
         gene or any other putative predictive factor in order to make decisions about postcancer aspirin use.
        </p>
        <p class="headingAnchor" id="H1599518867">
         <span class="h1">
          VITAMIN D STATUS
         </span>
         <span class="headingEndMark">
          —
         </span>
         An association between higher vitamin D levels and prognosis of CRC has been suggested. Whether higher levels of vitamin D supplementation can improve prognosis in conjunction with adjuvant chemotherapy for those with early stage disease is not yet known. Nevertheless, given the benefits of vitamin D repletion in terms of skeletal health and the possibility of better cancer-related outcomes, it seems reasonable to test serum vitamin D levels in patients with newly diagnosed CRC and to replete those with low levels (serum 25-hydroxyvitamin D [25(OH) D] &lt;20 ng/mL [50 nmol/L]).
        </p>
        <p>
         An association between vitamin D levels and prognosis of metastatic CRC has been observed. (See
         <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Issues related to vitamin D'
         </a>
         .)
        </p>
        <p>
         A similar relationship has been suggested in patients with earlier stage disease:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a subset of patients enrolled in the phase III Cancer and Leukemia Group B (CALGB) Alliance 89803 trial comparing adjuvant chemotherapy with weekly
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         /
         <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">
          leucovorin
         </a>
         with or without
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         , those in the highest quintile of predicted vitamin D score (which was based on race, geographic area of residence, dietary and supplemental vitamin D intake from food frequency questionnaires, body mass index [BMI], and physical activity, a method previously validated in metastatic CRC [
         <a href="#rid25">
          25
         </a>
         ]) had significantly improved recurrence-free and overall survival compared with those in the lowest quintile (adjusted hazard ratio [HR] for death or recurrence 0.62, 95% CI 0.44-0.86) [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another observational study suggests that low postoperative 25(OH) D levels may be associated with significantly worse survival, especially among patients with node-negative disease [
         <a href="#rid27">
          27
         </a>
         ]. The adjusted HRs for CRC-specific and all-cause mortality were 0.68 (95% CI 0.50-0.90) and 0.70 (95% CI 0.55-0.89), respectively, for highest versus lowest 25(OH) D tertiles, and for stage II disease, the HR for CRC-specific mortality was 0.44 (p = 0.004).
        </p>
        <p>
        </p>
        <p>
         In addition, a pooled analysis of data from seven randomized trials concluded that there was a clinically meaningful benefit of vitamin D supplementation on CRC survival outcomes (HR 0.70, 95% CI 0.48-0.93) [
         <a href="#rid28">
          28
         </a>
         ]. While the inclusion criteria, intervention doses, and outcomes varied among the studies, a beneficial effect of vitamin D supplementation was seen in trials specifically undertaken in CRC patients (HR for progression-free survival 0.65, 95% CI 0.36-0.94) and there was also a suggestive effect in incident CRC cases from other population-based trials (HR for CRC-specific survival 0.76, 95% CI 0.39-1.13). (See
         <a class="medical medical_review" href="/z/d/html/13915.html" rel="external">
          "Vitamin D and extraskeletal health", section on 'Cancer'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13915.html" rel="external">
          "Vitamin D and extraskeletal health", section on 'Mortality'
         </a>
         .)
        </p>
        <p>
         However, it is not certain that this association between poor vitamin D status and elevated CRC mortality is causal. There may be confounding influences relating to this observation, such as patients with more advanced disease being more likely indoors and less exposed to sunlight, and thus less replete with vitamin D. In addition, higher vitamin D levels may be acting as a surrogate for other healthy behaviors or biologically more favorable disease. Furthermore, whether higher levels of vitamin D supplementation can improve prognosis in conjunction with adjuvant chemotherapy is not yet known.
        </p>
        <p>
         The benefits of vitamin D repletion in terms of skeletal and extraskeletal health are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2022.html" rel="external">
          "Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13915.html" rel="external">
          "Vitamin D and extraskeletal health"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1081406018">
         <span class="h1">
          ISSUES FOR SURVIVORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recommendations for post-treatment cancer surveillance and issues for long-term survivors of colon cancer are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2493.html" rel="external">
          "Post-treatment surveillance after colorectal cancer treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14230.html" rel="external">
          "Approach to the long-term survivor of colorectal cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1559278913">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/15412.html" rel="external">
          "Patient education: Colon and rectal cancer (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/874.html" rel="external">
          "Patient education: Colon and rectal cancer (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/860.html" rel="external">
          "Patient education: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2270273219">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefits of adjunctive therapies
         </strong>
         – Beyond the benefits of chemotherapy and radiation therapy, several adjunctive factors have been associated with improved outcomes after treatment of early stage colorectal cancer (CRC), including interventions to achieve energy balance (ie, maintaining a healthy body weight, higher levels of physical activity), intake of
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and other nonsteroidal anti-inflammatory drugs (NSAIDs), vitamin D status, and coffee consumption. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diet and exercise
         </strong>
         – Given the mounting evidence that diet and exercise can modify prognosis, patients with early stage CRC should be encouraged to maintain a healthy weight and exercise regularly. (See
         <a class="local">
          'Diet and exercise'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          Aspirin
         </a>
         <strong>
          and other NSAIDs
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Several observational studies suggest that use of
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and other NSAIDs may improve survival among patients receiving treatment for early CRC, although randomized trials are needed to confirm benefit. It is not clear that all patients benefit. (See
         <a class="local">
          'Do all patients benefit?'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         While awaiting the results of prospective randomized trials, many oncologists, including some of the authors, recommend a daily dose of
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         to patients with resected early stage CRC unless they have a contraindication (preexisting coagulopathy, on anticoagulants, history of gastritis or peptic ulcer disease).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The optimal dose is not established, but the range is most commonly 75 to 325 mg daily. It is premature to consider testing individual patients for mutations in the
         <em>
          PIK3CA
         </em>
         gene in order to make decisions about postcancer
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         use. (See
         <a class="local">
          'Aspirin and other NSAIDs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vitamin D status
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         An association between higher vitamin D levels and prognosis in early stage CRC has been suggested. Whether higher levels of vitamin D supplementation can improve prognosis in conjunction with adjuvant chemotherapy is not yet known.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Nevertheless, given the benefits of vitamin D repletion in terms of skeletal health and the possibility of better cancer-related outcomes, it seems reasonable to test serum vitamin D levels in patients with newly diagnosed CRC and to replete those with low levels (serum 25-hydroxyvitamin D [25(OH) D] &lt;20 ng/mL [50 nmol/L]). (See
         <a class="local">
          'Vitamin D status'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348:891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348:883.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cook NR, Lee IM, Zhang SM, et al. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 2013; 159:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cardwell CR, Kunzmann AT, Cantwell MM, et al. Low-dose aspirin use after diagnosis of colorectal cancer does not increase survival: a case-control analysis of a population-based cohort. Gastroenterology 2014; 146:700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walker AJ, Grainge MJ, Card TR. Aspirin and other non-steroidal anti-inflammatory drug use and colorectal cancer survival: a cohort study. Br J Cancer 2012; 107:1602.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumari N, Mandaliya HA, Evans T, et al. Aspirin in the prevention of colorectal cancer recurrence. J Clin Oncol 2017; 35S: ASCO #578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009; 302:649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zell JA, Ziogas A, Bernstein L, et al. Nonsteroidal anti-inflammatory drugs: effects on mortality after colorectal cancer diagnosis. Cancer 2009; 115:5662.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bastiaannet E, Sampieri K, Dekkers OM, et al. Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer 2012; 106:1564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reimers MS, Bastiaannet E, Langley RE, et al. Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer. JAMA Intern Med 2014; 174:732.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ng K, Meyerhardt JA, Chan AT, et al. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst 2015; 107:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCowan C, Munro AJ, Donnan PT, Steele RJ. Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. Eur J Cancer 2013; 49:1049.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li P, Wu H, Zhang H, et al. Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis. Gut 2015; 64:1419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bains SJ, Mahic M, Myklebust TÅ, et al. Aspirin As Secondary Prevention in Patients With Colorectal Cancer: An Unselected Population-Based Study. J Clin Oncol 2016; 34:2501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elwood PC, Morgan G, Pickering JE, et al. Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published Studies. PLoS One 2016; 11:e0152402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hua X, Phipps AI, Burnett-Hartman AN, et al. Timing of Aspirin and Other Nonsteroidal Anti-Inflammatory Drug Use Among Patients With Colorectal Cancer in Relation to Tumor Markers and Survival. J Clin Oncol 2017; 35:2806.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Figueiredo JC, Jacobs EJ, Newton CC, et al. Associations of Aspirin and Non-Aspirin Non-Steroidal Anti-Inflammatory Drugs With Colorectal Cancer Mortality After Diagnosis. J Natl Cancer Inst 2021; 113:833.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNeil JJ, Nelson MR, Woods RL, et al. Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. N Engl J Med 2018; 379:1519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan AT. Aspirin and the USPSTF-What About Cancer? JAMA Oncol 2022; 8:1392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyerhardt JA, Shi Q, Fuchs CS, et al. Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial. JAMA 2021; 325:1277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012; 367:1596.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paleari L, Puntoni M, Clavarezza M, et al. PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies. Clin Oncol (R Coll Radiol) 2016; 28:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishihara R, Lochhead P, Kuchiba A, et al. Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA 2013; 309:2563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamada T, Cao Y, Qian ZR, et al. Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status. J Clin Oncol 2017; 35:1836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ng K, Wolpin BM, Meyerhardt JA, et al. Prospective study of predictors of vitamin D status and survival in patients with colorectal cancer. Br J Cancer 2009; 101:916.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fuchs MA, Yuan C, Sato K, et al. Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance). Ann Oncol 2017; 28:1359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zgaga L, Theodoratou E, Farrington SM, et al. Plasma vitamin D concentration influences survival outcome after a diagnosis of colorectal cancer. J Clin Oncol 2014; 32:2430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaughan-Shaw PG, Buijs LF, Blackmur JP, et al. The effect of vitamin D supplementation on survival in patients with colorectal cancer: systematic review and meta-analysis of randomised controlled trials. Br J Cancer 2020; 123:1705.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 116457 Version 18.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12621133" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : A randomized trial of aspirin to prevent colorectal adenomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12621132" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23856681" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24239563" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Low-dose aspirin use after diagnosis of colorectal cancer does not increase survival: a case-control analysis of a population-based cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23011483" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Aspirin and other non-steroidal anti-inflammatory drug use and colorectal cancer survival: a cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Aspirin in the prevention of colorectal cancer recurrence
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19671906" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Aspirin use and survival after diagnosis of colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19827153" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Nonsteroidal anti-inflammatory drugs: effects on mortality after colorectal cancer diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22454078" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Use of aspirin postdiagnosis improves survival for colon cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24687028" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25432409" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23182687" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25239119" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27247217" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Aspirin As Secondary Prevention in Patients With Colorectal Cancer: An Unselected Population-Based Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27096951" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published Studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28617623" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Timing of Aspirin and Other Nonsteroidal Anti-Inflammatory Drug Use Among Patients With Colorectal Cancer in Relation to Tumor Markers and Survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33528005" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Associations of Aspirin and Non-Aspirin Non-Steroidal Anti-Inflammatory Drugs With Colorectal Cancer Mortality After Diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30221595" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Effect of Aspirin on All-Cause Mortality in the Healthy Elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35900749" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Aspirin and the USPSTF-What About Cancer?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33821899" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23094721" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26712086" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23800934" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Aspirin use and risk of colorectal cancer according to BRAF mutation status.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28406723" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19690551" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Prospective study of predictors of vitamin D status and survival in patients with colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28327908" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25002714" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Plasma vitamin D concentration influences survival outcome after a diagnosis of colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32929196" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The effect of vitamin D supplementation on survival in patients with colorectal cancer: systematic review and meta-analysis of randomised controlled trials.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
